Relx (LON:REL) Shares Pass Above Two Hundred Day Moving Average of $1,795.49
Shares of Relx PLC (LON:REL) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1,795.49 and traded as high as $1,961.50. Relx shares last traded at $1,958.50, with a volume of 1,741,204 shares traded.
Several analysts have issued reports on REL shares. JPMorgan Chase & Co. upped their price target on shares of Relx from GBX 1,900 ($24.83) to GBX 1,950 ($25.48) and gave the stock an “overweight” rating in a research report on Friday, July 26th. Citigroup reaffirmed a “neutral” rating and set a GBX 1,880 ($24.57) price target on shares of Relx in a research report on Wednesday, August 14th. Barclays dropped their price target on shares of Relx from GBX 2,160 ($28.22) to GBX 2,100 ($27.44) and set an “overweight” rating on the stock in a research report on Friday, July 26th. UBS Group reaffirmed a “sell” rating on shares of Relx in a research report on Friday, July 26th. Finally, Liberum Capital reaffirmed a “buy” rating on shares of Relx in a research report on Friday, July 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of GBX 1,861.77 ($24.33).
The company has a market capitalization of $38.01 billion and a P/E ratio of 25.40. The company’s 50-day moving average price is GBX 1,939.20 and its two-hundred day moving average price is GBX 1,795.49. The company has a debt-to-equity ratio of 308.02, a current ratio of 0.45 and a quick ratio of 0.40.
About Relx (LON:REL)
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.